Erythropoietin ameliorates renal dysfunction during endotoxaemia

Nephrol Dial Transplant. 2007 Aug;22(8):2349-53. doi: 10.1093/ndt/gfm216. Epub 2007 Apr 16.

Abstract

Background: Sepsis has a high mortality (50-80%) when associated with acute renal failure (ARF). Oxidant injury and proinflammatory cytokines and chemokines have been shown to increase with endotoxaemia-related ARF. Since erythropoietin (EPO) has been demonstrated to possess anti-oxidant and anti-inflammatory properties, EPO may have therapeutic efficacy for treating ARF associated with endotoxaemia.

Methods: Wild-type mice were given 2.5 mg/kg of intraperitoneal (i.p.) endotoxin, lipopolysaccharide (LPS), and studied 16 h later. Thirty minutes prior to LPS, the mice were given either EPO or vehicle.

Results: During endotoxaemia, EPO was found to significantly attenuate the renal dysfunction, as assessed by glomerular filtration rate (48.1 +/- 12.4 microl/min vs 136.7 +/- 30.2, P < 0.05). Renal blood flow and mean arterial pressure were not significantly different between the two groups. The renal dysfunction during endotoxaemia was associated with a decrease in renal superoxide dismutase (SOD). The EPO-related renal protection was associated with reversal of the effects of endotoxin on renal SOD.

Conclusion: This is the first demonstration of a renal protective effect of EPO on endotoxin-related renal dysfunction.

MeSH terms

  • Animals
  • Cytokines / metabolism
  • Endotoxemia / complications
  • Endotoxemia / drug therapy*
  • Erythropoietin / therapeutic use*
  • Glomerular Filtration Rate
  • Inflammation
  • Kidney / metabolism
  • Kidney Diseases / complications
  • Kidney Diseases / drug therapy*
  • Lipopolysaccharides / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nitric Oxide / metabolism
  • Sepsis
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Cytokines
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Erythropoietin
  • Nitric Oxide